EPRX · Nasdaq · CIK 0001581178

EUPRAXIA PHARMACEUTICALS INC.

EUPRAXIA PHARMACEUTICALS INC.’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 22, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $0 and net income of -$38.6M, according to its XBRL data on EDGAR. Its EDGAR record lists 0 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$0
Net income, FY2025
-$38.6M
Form 4 filings on record, past 12 months
0

Company overview

Legal name (as filed)
EUPRAXIA PHARMACEUTICALS INC.
Ticker
EPRX
SEC Central Index Key (CIK)
0001581178
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
VANCOUVER
State or country of incorporation
British Columbia, Canada
Fiscal year ends
December 31
SEC filer category
<br>Emerging growth company
Position in SEC ticker list
#2900 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from EUPRAXIA PHARMACEUTICALS INC.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2022$0FY2023$0FY2024$0FY2025
Net income
-$18.5MFY2022-$28.2MFY2023-$25.5MFY2024-$38.6MFY2025
EPRX annual results
ItemFY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—$0$0$0
Net income-$18.5M-$28.2M-$25.5M-$38.6M
Diluted EPS-$0.96-$1.17-$0.76-$1.03
Total assets$19.1M$20.3M$34.9M$86.2M
Cash and equivalents$18.3M$19.3M$33.1M$80.6M

XBRL tags used: revenue = Revenues; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

EPRX latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Oct 22, 20266-KReport of a foreign private issuer· period Oct 22, 2026Document · Index
Mar 13, 202640-FAnnual report of certain Canadian issuers· period Dec 31, 2025Document · Index

Recent SEC filings

The 40 newest documents filed by or about EUPRAXIA PHARMACEUTICALS INC., by form type:

6-K ×28SUPPL ×3SCHEDULE 13G/A ×3EFFECT ×1F-10/A ×1F-X ×1F-10 ×1SCHEDULE 13D/A ×140-F ×1
EPRX recent filings
FiledFormWhat it isOriginal
Oct 22, 20266-KReport of a foreign private issuer· period Oct 22, 2026Document · Index
Oct 15, 20266-KReport of a foreign private issuer· period Oct 15, 2026Document · Index
Oct 9, 20266-KReport of a foreign private issuer· period Oct 9, 2026Document · Index
Sep 30, 20266-KReport of a foreign private issuer· period Sep 30, 2026Document · Index
Sep 8, 20266-KReport of a foreign private issuer· period Sep 8, 2026Document · Index
Sep 2, 2026SUPPLSUPPLDocument · Index
Aug 24, 2026EFFECTEFFECTDocument · Index
Aug 19, 2026F-10/AF-10/ADocument · Index
Aug 13, 20266-KReport of a foreign private issuer· period Aug 13, 2026Document · Index
Aug 13, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 11, 20266-KReport of a foreign private issuer· period Aug 11, 2026Document · Index
Aug 6, 2026F-XF-XDocument · Index
Aug 6, 2026F-10F-10Document · Index
Jul 15, 20266-KReport of a foreign private issuer· period Jul 15, 2026Document · Index
Jul 13, 20266-KReport of a foreign private issuer· period Jul 13, 2026Document · Index
Jul 7, 20266-KReport of a foreign private issuer· period Jul 7, 2026Document · Index
Jun 22, 20266-KReport of a foreign private issuer· period Jun 19, 2026Document · Index
May 29, 20266-KReport of a foreign private issuer· period Jun 18, 2026Document · Index
May 29, 20266-KReport of a foreign private issuer· period May 28, 2026Document · Index
May 28, 20266-KReport of a foreign private issuer· period May 28, 2026Document · Index
May 12, 20266-KReport of a foreign private issuer· period May 12, 2026Document · Index
May 12, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 6, 20266-KReport of a foreign private issuer· period May 6, 2026Document · Index
May 5, 20266-KReport of a foreign private issuer· period May 5, 2026Document · Index
May 1, 20266-KReport of a foreign private issuer· period May 1, 2026Document · Index
Apr 22, 20266-KReport of a foreign private issuer· period Apr 22, 2026Document · Index
Apr 21, 20266-KReport of a foreign private issuer· period Apr 21, 2026Document · Index
Apr 15, 20266-KReport of a foreign private issuer· period Apr 14, 2026Document · Index
Apr 15, 20266-KReport of a foreign private issuer· period Apr 14, 2026Document · Index
Mar 17, 20266-KReport of a foreign private issuer· period Mar 17, 2026Document · Index
Mar 16, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Mar 13, 202640-FAnnual report of certain Canadian issuers· period Dec 31, 2025Document · Index
Mar 6, 20266-KReport of a foreign private issuer· period Feb 23, 2026Document · Index
Feb 20, 2026SUPPLSUPPLDocument · Index
Feb 20, 20266-KReport of a foreign private issuer· period Feb 19, 2026Document · Index
Feb 20, 20266-KReport of a foreign private issuer· period Feb 20, 2026Document · Index
Feb 19, 20266-KReport of a foreign private issuer· period Feb 19, 2026Document · Index
Feb 18, 2026SUPPLSUPPLDocument · Index
Feb 18, 20266-KReport of a foreign private issuer· period Feb 18, 2026Document · Index
Feb 17, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index

Insider filing activity

0 Form 4 filings appear in EUPRAXIA PHARMACEUTICALS INC.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001581178 and XBRL company facts. EUPRAXIA PHARMACEUTICALS INC. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.